Evidence map›Paper›PMID 29445239›Full record

ArticleScientific reports2018

The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.

Andrew S Gilder, Letizia Natali, Danielle M Van Dyk, Cristina Zalfa, Michael A Banki, Donald P Pizzo, Huawei Wang, Richard L Klemke, Elisabetta Mantuano, Steven L Gonias

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. CTHRC1Scientific reports · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Update on Novel Targeted Therapy for Pleural Organization and Fibrosis.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Andrew S GilderDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA.
Letizia NataliDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA.
Danielle M Van DykDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA.
Cristina ZalfaDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA.
Michael A BankiDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA.
Donald P PizzoDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA.
Huawei WangDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA.ORCID 0000-0001-5481-303X
Richard L KlemkeDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA.
Elisabetta MantuanoDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA.ORCID 0000-0001-5728-9261
Steven L GoniasDepartment of Pathology, University of California San Diego, La Jolla, California, 92093, USA. sgonias@ucsd.edu.
University of California San Diego · US

Funding

Vascular communication in metastatic brain colonizationR01CA184594 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KLEMKE, RICHARD L. · 2014 to 2018
$1.6M
Targeting the Urokinase Receptor in Glioblastoma MultiformeR01CA169096 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GONIAS, STEVEN L. · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA169096NCI NIH HHS R01 CA184594
6 · The paper itself

Abstract

PLAUR encodes the urokinase receptor (uPAR), which promotes cell survival, migration, and resistance to targeted cancer therapeutics in glioblastoma cells in culture and in mouse model systems. Herein, we show that patient survival correlates inversely with PLAUR mRNA expression in gliomas of all grades, in glioblastomas, and in the subset of glioblastomas that demonstrate the mesenchymal gene expression signature. PLAUR clusters with genes that define the more aggressive mesenchymal subtype in transcriptome profiles of glioblastoma tissue and glioblastoma cells in neurospheres, which are enriched for multipotent cells with stem cell-like qualities. When PLAUR was over-expressed or silenced in glioblastoma cells, neurosphere growth and expression of mesenchymal subtype biomarkers correlated with uPAR abundance. uPAR also promoted glioblastoma cell survival in neurospheres. Constitutively-active EGF Receptor (EGFRvIII) promoted neurosphere growth; however, unlike uPAR, EGFRvIII did not induce the mesenchymal gene expression signature. Immunohistochemical analysis of human glioblastomas showed that uPAR is typically expressed by a small sub-population of the cancer cells; it is thus reasonable to conclude that this subpopulation of cells is responsible for the effects of PLAUR on patient survival. We propose that uPAR-expressing glioblastoma cells demonstrate a mesenchymal gene signature, an increased capacity for cell survival, and stem cell-like properties.

Indexed as

AnimalsBrain NeoplasmsCell MovementCell ProliferationCell SurvivalCohort StudiesDisease Models, AnimalGene Expression Regulation, NeoplasticGlioblastomaHumansMesenchymal Stem CellsMiceReceptors, Urokinase Plasminogen ActivatorRNA, Small InterferingSurvival AnalysisTissue Array AnalysisPLAUR protein, humanReceptors, Urokinase Plasminogen ActivatorRNA, Small Interfering

Identifiers

PMID29445239
PMCPMC5813209
OpenAlexW2805797612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.